Progressive supranuclear palsy (PSP) is a rare brain disease that destroys nerve cells in areas controlling movement, balance, vision, speech, and thinking. It affects roughly 7 out of every 100,000 people and progresses to death in 5 to 7 years on average. PSP is often mistaken for Parkinson’s disease early on, but it follows a distinct and generally faster course.
What Happens in the Brain
PSP belongs to a family of diseases called tauopathies, where a protein called tau builds up abnormally inside brain cells. In a healthy brain, tau helps stabilize the internal scaffolding that cells need to function. In PSP, a specific form of tau (known as four-repeat tau) clumps into tangles and threads that poison neurons from the inside out.
The damage concentrates in a group of deep brain structures that act as relay stations for movement: the subthalamic nucleus, the globus pallidus, and the substantia nigra. These regions shrink as neurons die. The brainstem, which controls eye movements and basic functions like swallowing, is hit especially hard. As the disease advances, tau pathology spreads outward into the motor cortex and other cortical areas, which is when cognitive symptoms become more noticeable. On brain imaging, one of the clearest signs is a shrunken midbrain, visibly smaller in PSP patients than in people with Parkinson’s.
Early Signs and Core Symptoms
The hallmark of PSP is trouble moving the eyes, particularly looking downward. This develops gradually and can start as blurred vision, difficulty reading, or trouble making eye contact during conversation. Some people spill food because they can’t see the plate in front of them. Over time, vertical eye movements become severely restricted, which is the “supranuclear gaze palsy” in the disease’s name.
Balance problems appear early and are often the first thing people notice. Falls, especially backward falls, can begin within the first year. This is a key difference from Parkinson’s, where serious balance trouble usually comes later. The falls in PSP tend to be sudden and unexplained, as if the person simply toppled over without warning.
Other symptoms develop as the disease progresses:
- Stiffness and slowness, particularly in the neck and trunk rather than the hands and arms
- Slurred or slowed speech that becomes progressively harder to understand
- Swallowing difficulty, which eventually raises the risk of choking and pneumonia
- Cognitive changes, including slowed thinking, impulsivity, and apathy rather than the memory loss typical of Alzheimer’s
- Reduced blinking, which leads to dry eyes and chronic eye irritation
Two Main Forms of PSP
Not everyone with PSP looks the same. The disease has several recognized subtypes, but two account for the majority of cases.
Richardson syndrome is the classic form, making up about 54% of confirmed cases. It announces itself with early falls, balance problems, vertical gaze palsy, and cognitive decline. It progresses faster, with an average disease duration of about 5.9 years. Roughly two-thirds of people with this form are men.
PSP-parkinsonism accounts for about 32% of cases and looks much more like Parkinson’s disease at the start. People with this form tend to have tremor, slowness on one side of the body, and even a moderate initial response to Parkinson’s medications. Because of this overlap, many are initially diagnosed with Parkinson’s. PSP-parkinsonism progresses more slowly, with an average disease duration of about 9.1 years, and affects men and women roughly equally.
How PSP Differs From Parkinson’s
The confusion between PSP and Parkinson’s is common, even among doctors. Several features help tell them apart.
The most important is the response to levodopa, the standard Parkinson’s medication. People with Parkinson’s typically get dramatic improvement. People with PSP get little to no benefit. Some clinicians use a trial of levodopa as a diagnostic test for exactly this reason.
Falls in PSP come early, often within the first year or two. In Parkinson’s, significant balance problems usually appear much later. The stiffness in PSP tends to center on the neck and trunk, giving people a stiff, upright posture, while Parkinson’s more often causes a stooped, forward-leaning posture. Eye movement problems, particularly the inability to look downward, are characteristic of PSP and uncommon in early Parkinson’s.
Brain imaging can also help. The midbrain is measurably smaller in PSP. In one study, midbrain volume averaged 8.74 milliliters in PSP patients compared to 10.19 milliliters in Parkinson’s patients, a significant difference that doctors can detect on MRI.
How Common Is PSP
PSP is rare but probably underdiagnosed. A large meta-analysis pooling data from multiple studies estimated the prevalence at about 7 per 100,000 people, with roughly 1 new case per 100,000 people each year. Because the symptoms overlap with Parkinson’s and other conditions, many cases are only confirmed after death through brain tissue examination. The true numbers may be higher than these estimates suggest.
Most people develop symptoms in their 60s or 70s. PSP is almost never seen before age 40. No clear genetic cause has been identified for the vast majority of cases, though certain genetic variations in the tau gene region appear to increase susceptibility.
Treatment and Daily Management
No medication can slow or stop PSP. Treatment focuses entirely on managing symptoms and maintaining quality of life for as long as possible.
Parkinson’s medications like levodopa are often tried, but the benefit is minimal in most PSP patients. Dopamine-boosting drugs may provide modest, short-lived relief for some stiffness and slowness, particularly in the PSP-parkinsonism subtype. Antidepressants are sometimes used for mood changes. Botulinum toxin injections can help with specific problems like involuntary eyelid closure, jaw clenching, or neck rigidity.
Physical therapy is one of the most practical interventions. A therapist can teach strategies to reduce fall risk and maintain mobility. Speech therapy helps with both communication and swallowing as those functions decline. Weighted walkers (rather than standard ones) are often recommended because PSP causes backward falls, and a heavier walker provides a forward counterbalance.
Eye drops or lubricants become important because the reduced blink rate in PSP leads to chronic dry eyes and irritation. Prism glasses can sometimes compensate for the inability to look downward, making it easier to read or eat.
As swallowing worsens, dietary changes become necessary. Thickened liquids and softer foods reduce choking risk. In later stages, some families face decisions about feeding tubes, though this is a deeply personal choice that depends on individual values and goals of care.
What the Disease Course Looks Like
PSP follows a steady downhill course, though the speed varies. In the classic Richardson syndrome form, most people need a wheelchair within 3 to 5 years of symptom onset. The PSP-parkinsonism form moves more slowly, and some people maintain walking ability for longer.
The later stages bring increasing dependence. Speech may become unintelligible, swallowing becomes dangerous, and cognitive changes can progress to a degree that resembles dementia, though the pattern differs from Alzheimer’s. The most common life-threatening complications relate to swallowing problems: aspiration pneumonia, where food or liquid enters the lungs, is a leading cause of death. Average survival is 5 to 7 years from symptom onset, though some people live longer, particularly those with PSP-parkinsonism.